慢性乙型肝炎患者肝组织基质金属蛋白酶组织抑制物-1表达及其意义*

doi:10.3969/j.issn.1672-5069.2014.03.007

实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (3): 245-249.doi: 10.3969/j.issn.1672-5069.2014.03.007

慢性乙型肝炎患者肝组织基质金属蛋白酶组织抑制物-1表达及其意义^*

朱传龙, 李毓雯, 李文庭, 李宜, 高人焘

230001 合肥市安徽医科大学附属省立医院感染病科（朱传龙,李文庭,李宜,高人焘）; 儿内科（李毓雯）

收稿日期:2013-11-29 出版日期:2014-06-30 发布日期:2016-04-11
通讯作者: 高人焘,E-mail：rentaogao@sohu.com
作者简介:朱传龙,男,33岁,医学博士,副主任医师。主要从事病毒性肝炎的基础与临床研究
基金资助:
国家自然科学基金资助项目（81271713）; 安徽省第五批优秀青年科技基金滚动支持项目（1308085JGD09）; 安徽医科大学校长基金资助项目（2011xkj074）

Clinical significance of tissue inhibitor of metalloproteinases-1 in livers of patients with chronic hepatitis B

Zhu Chuanlong, Li Yuwen, Li Wenting

Department of Infectious Disease,Anhui Provincial Hospital,Anhui Medical University,Hefei 230001,Anhui Province,China

Received:2013-11-29 Online:2014-06-30 Published:2016-04-11

摘要/Abstract

摘要： 目的分析慢性乙型肝炎患者血清和肝组织基质金属蛋白酶组织抑制物-1（TIMP-1）表达水平与肝纤维化分期的相关性。方法分别采用免疫组化法和双抗体夹心酶联免疫吸附法检测患者肝组织和血清TIMP-1表达水平,分析两者相关性; 对159例慢性乙型肝炎患者行肝活检病理学检查,以组织学活动指数（HAI）予以分级（G）和分期（S）,分析慢性乙型肝炎患者血清TIMP-1水平与HAI分级和纤维化分期的相关性。结果慢性乙型肝炎患者肝组织TIMP-1表达水平与其血清水平呈显著性正相关（r=0.9521,P<0.01）;不同肝纤维化分期（S₁~S₄）慢性乙型肝炎患者血清TIMP-1水平差异显著（P<0.05）,且血清TIMP-1水平与肝纤维化分期呈正相关（r=0.704, P<0.01）,但不同炎症分级的慢性乙型肝炎患者血清TIMP-1水平差异无显著性。结论血清TIMP-1水平可以较好地反应肝脏纤维化程度,且不受肝组织炎症分级的影响,有望被用于肝组织纤维化程度的临床无创评估。

关键词: 慢性乙型肝炎, 基质金属蛋白酶组织抑制物-1, 肝纤维化, 炎症

Abstract: Objective To evaluate the expression of tissue inhibitor of metalloproteinases-1 （TIMP-1） in livers of patients with chronic hepatitis B（CHB） and to explore the potential relationship between TIMP-1 level and hepatic fibrosis progression. Methods The tissue and serum levels of TIMP-1 were determined by immunohistochemistry and double-antibody sandwich enzyme-linked immunoadsorbent assay,respectively,and their correlation was determined. One hundred and fifty-nine patients with CHB underwent liver biopsy and their liver histological activity index （HAI） and fibrosis （S） were determined. The correlation between the serum TIMP-1 levels and HAI grading and staging was analyzed. Results The expression of TIMP-1 in liver tissues were positively correlated to serum TIMP-1 levels in CHB patients （r=0.9521,P<0.01）;Serum TIMP-1 levels were significant different among patients with different liver fibrosis stages（S₁ to S₄）（P<0.05）,and a positive correlation between serum TIMP-1 level and hepatic fibrosis staging was found（r=0.704,P<0.01）;However,there were no significant differences in serum TIMP-1 levels among patients with different liver inflammatory grades. ConclusionsSerum TIMP-1 level is not affected by liver inflammatory grades and is promising in non-invasive clinical evaluation of liver fibrosis.

Key words: Chronic hepatitis B, Tissue inhibitor of metalloproteinases-1, Hepatic fibrosis, Inflammation

朱传龙, 李毓雯, 李文庭, 李宜, 高人焘. 慢性乙型肝炎患者肝组织基质金属蛋白酶组织抑制物-1表达及其意义^*[J]. 实用肝脏病杂志, 2014, 17(3): 245-249.

Zhu Chuanlong, Li Yuwen, Li Wenting. Clinical significance of tissue inhibitor of metalloproteinases-1 in livers of patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 245-249.

参考文献

[1] Boeker KH,Haberkorn CI,Michels D,et al. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta,2002,316（1-2）:71-81.
[2] Lichtinghagen R,Pietsch D,Bantel H,et al. The enhanced liver fibrosis（ELF） score:normal values,influence factors and proposed cut-off values. J Hepatol,2013,59（2）:236-242.
[3] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[4] Rosenberg WM. Rating fibrosis progression in chronic liver diseases. J Hepatol,2003,38（3）:357-360.
[5] Torok NJ. Recent advances in the pathogenesis and diagnosis of liver fibrosis. J Gastroenterol,2008,43（5）:315-321.
[6] Gagliano N,Arosio B,Grizzi F,et al. Reduced collagenolytic activity of matrix metalloproteinases and development of liver fibrosis in the aging rat. Mech Ageing Dev,2002,123:413-425.
[7] Watanabe T,Niioka M,Ishikawa A,et al. Dynamic change of cells expressing MMP-2 mRNA and MT1-MMP mRNA in the recovery from liver fibrosis in the rat. J Hepatol,2001,35:465-473.
[8] Lichtinghagen R,Michels D,Haberkorn CI,et al. Matrix metalloproteinase（MMP）-2,MMP-7,and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C.J Hepatol,2001,34:239-247.
[9] Yoshiji H,Kuriyama S,Miyamoto Y,et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology,2000,32:1248-1254.
[10] Vaillant B,Chiaramonte MG,Cheever AW,et al. Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol,2001,167:7017-7026.
[11] McCrudden R,Iredale JP. Liver fibrosis,the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol 2000,15:1159-1168.
[12] Ueno T,Tamaki S,Sugawara H,et al. Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases.J Hepatol,1996,24:177-184.
[13] Nie QH,Zhu CL,Zhang YF,et al. Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis. Dig Dis Sci,2010,55:1286-1295.
[14] Boker KH, Pehle B,Steinmetz C,et al. Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis.Hepatogastroenterology,2000,47（33）:812-819.
[15] Heymans S, Schroen B,Vermeersch P,et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation,2005,112（8）:1136-1144.
[16] Sam L,Nicolas R,Brain GO,et al. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Am J Respir Crit Care Med,2000,162（4）:1355-1360.
[17] Jenny TM,Donald PT, Paula NB, et al. All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Chest,2003,124:1724-1732.
[18] Ruiz V,Ordonez RM,Berumen J, et al. Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol,2003,285（5）:L1026-1036.
[19] Nee LE,McMorrow T,Campbell E,et al. TNF-alpha and IL-1beta-mediated regulation of MMP-9 and TIMP-1 in renal proximal tubular cells. Kidney Int,2004,66（4）:1376-1386.
[20] Chevalier RL. Pathogenesis of renal injury in obstructive uropathy. Curr Opin Pediatr,2006,18（2）:153-160.
[21] Murawaki Y,Ikuta Y,Kawasaki H. Clinical usefulness of serum tissue inhibitor of metalloproteinases（TIMP）-2 assay in patients with chronic liver disease in comparison with serum TIMP-1.Clin Chim Acta,1999,281（1-2）:109-120.

慢性乙型肝炎患者肝组织基质金属蛋白酶组织抑制物-1表达及其意义^*

Clinical significance of tissue inhibitor of metalloproteinases-1 in livers of patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[2]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[3]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[6]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[7]	汪道伟, 方坚, 范凌. 自身免疫性肝炎患者血清IL-21和趋化因子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 844-847.
[8]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[9]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[10]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[11]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[12]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[13]	张莹, 王洪岩, 迟程, 徐有青. LPS诱导的HepG2细胞NOTCH与LPS-TLR4-NF-κB炎症信号通路的“会话”研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 470-473.
[14]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[15]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.